ONCR News and Press, Oncorus Inc. From 06/02/23

2023-06-02 12:22:40 ET Oncorus ( NASDAQ: ONCR ) said that it may have to seek bankruptcy protection as the biopharma lays off almost its entire staff. Shares are down ~43% in Friday trading. Included in the layoffs are the company's CEO, COO, and CMO. Its interim CFO i...

ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that, in response to challenges associated with raising additio...

2023-05-26 07:32:35 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time for another dive into the biggest pre-market stock movers as we check out what’s happening on Friday! Moving stocks this morning are clinical trial results, earnings...

2023-05-22 16:53:38 ET Oncorus press release ( NASDAQ: ONCR ): Q1 GAAP EPS of -$1.18 misses by $0.48 . Cash, cash equivalents and investments totaled $45.0 million as of March 31, 2023 compared to $62.2 million as of December 31, 2022. Guidance: Oncorus expects...

IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company f...

2023-03-24 09:36:20 ET Oncorus press release ( NASDAQ: ONCR ): Q4 GAAP EPS of -$0.81. Cash, cash equivalents and investments totaled $62.2 million as of December 31, 2022 For further details see: Oncorus GAAP EPS of -$0.81

Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicines On track to submit IND for ONCR-021 in mid-2023 Preclinical data featured in Nature Communications support self-amplifying RNA platform and promise of repeat IV-administration Ended the quar...

2023-03-17 16:16:22 ET Summary Here's a long list of biopharmas exposed to SVB Financial Group. Many of these deposits will be uninsured. However, since SVB Financial Group was quite solvent otherwise, much of these deposits should be recoverable by these small companies. ...

Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong’s mRNA expertise Opportunity for future license, manufacturing and supply agreement for formulated drug candid...

Company now focused on the development of ONCR-021, Oncorus’ lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains on track for IND submission in mid-2023 Phase 1 clinical trial of ONCR-177 in patients with advanced disease is being d...